Harris, Lyndsay N.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,860

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 470

Requirement for CDK4 kinase function in breast cancer

Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 429

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 294

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 245

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial

Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 106

The Yale Fitness Intervention Trial in female cancer survivors: Cardiovascular and physiological outcomes

Knobf, M. T., Jeon, S., Smith, B., Harris, L., Thompson, S., Stacy, M. R., Insogna, K., & Sinusas, A. J. (2017) · Heart & Lung

Cancer survivorship and careCardiovascular and exercise physiology

Cited by 26